Literature DB >> 19369472

Peripheral arterial stiffness and endothelial dysfunction in idiopathic and scleroderma associated pulmonary arterial hypertension.

Nir Peled1, David Shitrit, Benjamin D Fox, Dekel Shlomi, Anat Amital, Daniele Bendayan, Mordechai R Kramer.   

Abstract

OBJECTIVE: Pulmonary endothelial dysfunction and increased reflection of pulmonary pressure waves have been reported in pulmonary arterial hypertension (PAH). However, the systemic vascular involvement is not fully understood. Our study focused on the systemic arterial stiffness and endothelial involvement in idiopathic and scleroderma associated PAH.
METHODS: Peripheral arterial stiffness and endothelial function were evaluated in 38 patients with idiopathic (n = 28) and scleroderma associated (n = 10) PAH, and 21 control subjects (13 healthy; 8 with scleroderma and normal pulmonary pressure). All participants underwent clinical and cardiopulmonary evaluation. Arterial stiffness was measured through the fingertip tonometry derived augmentation index (AI), which is the boost increase in the late systolic pressure wave after the initial systolic shoulder. Endothelial function was measured by forearm blood flow dilatation response to brachial artery occlusion by a noninvasive plethysmograph (EndoPAT 2000), which is associated with nitric oxide-dependent vasodilatation and yields a peripheral arterial tone (PAT) ratio.
RESULTS: Mean systolic pulmonary pressure was 70.5 +/- 21.6 mm Hg (idiopathic-PAH) and 69.3 +/- 20 mm Hg (scleroderma-PAH). AI was higher in scleroderma patients (10.5% +/- 19.6% in healthy controls, 9.0% +/- 21.5% in idiopathic-PAH, 20.1% +/- 19.1% in scleroderma-PAH, and 24.4% +/- 18.9% in scleroderma-controls; nonsignificant). PAT ratio was significantly lower (p < 0.05) than control values in idiopathic-PAH and scleroderma-PAH (PAT ratio: control 2.20 +/- 0.25; idiopathic 1.84 +/- 0.51; scleroderma 1.66 +/- 0.66). AI was not correlated to endothelial dysfunction. There were no differences between the 2 PAH patient groups in age, body mass index, New York Heart Association classification, or 6-min walk test.
CONCLUSION: Our study shows a trend towards increased arterial stiffness in scleroderma (nonsignificant), and also peripheral endothelial dysfunction in idiopathic-PAH and in scleroderma-PAH. These findings suggest involvement of different vessels in scleroderma-PAH compared to idiopathic-PAH.

Entities:  

Mesh:

Year:  2009        PMID: 19369472     DOI: 10.3899/jrheum.081088

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  31 in total

1.  Brachial artery diameter and the right ventricle: the Multi-Ethnic Study of Atherosclerosis-right ventricle study.

Authors:  Christopher T Dibble; Daichi Shimbo; R Graham Barr; Emilia Bagiella; Harjit Chahal; Corey E Ventetuolo; David M Herrington; Joao A C Lima; David A Bluemke; Steven M Kawut
Journal:  Chest       Date:  2012-12       Impact factor: 9.410

2.  Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension.

Authors:  Jens Vogel-Claussen; Jan Skrok; Monda L Shehata; Sukhminder Singh; Christopher T Sibley; Danielle M Boyce; Noah Lechtzin; Reda E Girgis; Steven C Mathai; Thomas A Goldstein; Jie Zheng; João A C Lima; David A Bluemke; Paul M Hassoun
Journal:  Radiology       Date:  2010-10-22       Impact factor: 11.105

Review 3.  Respiratory and limb muscle dysfunction in pulmonary arterial hypertension: a role for exercise training?

Authors:  Marios Panagiotou; Andrew J Peacock; Martin K Johnson
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

4.  Relationship between Peripheral Arterial Stiffness and Estimated Pulmonary Pressure by Echocardiography in Systemic Sclerosis.

Authors:  Burabha Pussadhamma; Wannipa Suwannakrua; Panorkwan Toparkngarm; Chaiyasith Wongvipaporn; Chingching Foocharoen; Ratanavadee Nanagara
Journal:  Acta Cardiol Sin       Date:  2017-09       Impact factor: 2.672

5.  Kinetics of skeletal muscle O2 delivery and utilization at the onset of heavy-intensity exercise in pulmonary arterial hypertension.

Authors:  Priscila B Barbosa; Eloara M V Ferreira; Jaquelina S O Arakaki; Luciana S Takara; Juliana Moura; Rúbia B Nascimento; Luiz E Nery; J Alberto Neder
Journal:  Eur J Appl Physiol       Date:  2011-01-12       Impact factor: 3.078

6.  Systemic endothelial dysfunction in children with idiopathic pulmonary arterial hypertension correlates with disease severity.

Authors:  Debbie Friedman; Jacqueline Szmuszkovicz; Miklos Rabai; Jon A Detterich; Jondavid Menteer; John C Wood
Journal:  J Heart Lung Transplant       Date:  2012-03-21       Impact factor: 10.247

7.  Sublingual microcirculation in pulmonary arterial hypertension.

Authors:  Luma Dababneh; Frank Cikach; Laith Alkukhun; Raed A Dweik; Adriano R Tonelli
Journal:  Ann Am Thorac Soc       Date:  2014-05

Review 8.  Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.

Authors:  Nils P Nickel; Ke Yuan; Peter Dorfmuller; Steeve Provencher; Yen-Chun Lai; Sebastien Bonnet; Eric D Austin; Carl D Koch; Alison Morris; Frédéric Perros; David Montani; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Respir Crit Care Med       Date:  2020-01-15       Impact factor: 21.405

9.  Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Ryan J Tedford; James O Mudd; Reda E Girgis; Stephen C Mathai; Ari L Zaiman; Traci Housten-Harris; Danielle Boyce; Benjamin W Kelemen; Anita C Bacher; Ami A Shah; Laura K Hummers; Fredrick M Wigley; Stuart D Russell; Rajeev Saggar; Rajan Saggar; W Lowell Maughan; Paul M Hassoun; David A Kass
Journal:  Circ Heart Fail       Date:  2013-09-01       Impact factor: 8.790

10.  Mechanics and Function of the Pulmonary Vasculature: Implications for Pulmonary Vascular Disease and Right Ventricular Function.

Authors:  Steven Lammers; Devon Scott; Kendall Hunter; Wei Tan; Robin Shandas; Kurt R Stenmark
Journal:  Compr Physiol       Date:  2012-01-01       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.